EUVIMEDEUVIMED entdecken
Open Access

Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Richard Sparks, Nicholas Baca, Bernd J Krause, Michael Lassmann, Walter Jentzen, Jun Tang, Daniela Chicco, Patrick Klein, Lars Blumenstein und 2 weitere

Journal of Nuclear Medicine · 2024-01 · 65 (1) · 71-78

DOI: 10.2967/jnumed.123.265448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 30.11.2023. Verfasst von Ken Herrmann und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany; ken.herrmann@uk…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the VISION trial, [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) plus protocol-permitted standard of care significantly improved overall survival and radiographic progression-free survival compared with standard of care alone in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. This VISION dosimetry substudy quantified absorbed doses of 177Lu-PSMA-617 in the kidneys and other organs.

Methods

Participants were a separate cohort of 30 nonrandomized patients receiving standard of care plus 177Lu-PSMA-617 at 7.4 GBq per cycle for up to 6 cycles. Blood samples, whole-body conjugate planar image scintigraphy, and abdominal SPECT/CT images were collected. SPECT/CT images were collected at 2, 24, 48, and 168 h after administration in cycle 1 and at a single time point 48 h after administration in cycles 2-6. Outcomes were absorbed dose per unit activity per cycle and cumulative absorbed dose over all cycles. Cumulative absorbed doses were predicted by extrapolation from cycle 1, and calculation of observed values was based on measurements of cycle 1 and cycles 2-6. Safety was also assessed.

Results

Mean (±SD) absorbed doses per cycle in the kidneys were 0.43 ± 0.16 Gy/GBq in cycle 1 and 0.44 ± 0.21 Gy/GBq in cycles 2-6. The observed and predicted 6-cycle cumulative absorbed doses in the kidneys were 15 ± 6 and 19 ± 7 Gy, respectively. Observed and predicted cumulative absorbed doses were similar in other at-risk organs. Safety findings were consistent with those in the VISION study; no patients experienced renal treatment-emergent adverse events of a grade higher than 3.

Conclusion

The renal cumulative absorbed 177Lu-PSMA-617 dose was below the established limit. 177Lu-PSMA-617 had a good overall safety profile, and low renal radiotoxicity was not a safety concern. Cumulative absorbed doses in at-risk organs over multiple cycles can be predicted by extrapolation from cycle 1 data in patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansRadiopharmaceuticalsDipeptidesProstate-Specific AntigenHeterocyclic Compounds, 1-RingKidneyLutetium

Stichwörter der Autor:innen

177Lumetastatic castration-resistant prostate cancerprostate-specific membrane antigenradioligand therapy

Substanzen

PSMA-617RadiopharmaceuticalsDipeptidesProstate-Specific AntigenHeterocyclic Compounds, 1-RingLutetium

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany; ken.herrmann@uk-essen.de.
  • Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
  • Technical University of Munich, Munich, Germany.
  • CDE Dosimetry Services, Knoxville, Tennessee.
  • Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany.
  • Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.

Zitieren

APA

Herrmann, K., Rahbar, K., Eiber, M., Sparks, R., Baca, N., Krause, B. J., Lassmann, M., Jentzen, W., Tang, J., Chicco, D., Klein, P., Blumenstein, L., Basque, J. R., & Kurth, J. (2024). Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. Journal of Nuclear Medicine, 65(1), 71-78. https://doi.org/10.2967/jnumed.123.265448

Vancouver

Herrmann K, Rahbar K, Eiber M, Sparks R, Baca N, Krause BJ, et al. Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. Journal of Nuclear Medicine. 2024;65(1):71-78. doi:10.2967/jnumed.123.265448

BibTeX
@article{Herrmann2024,
  author = {Herrmann, Ken and Rahbar, Kambiz and Eiber, Matthias and Sparks, Richard and Baca, Nicholas and Krause, Bernd J and Lassmann, Michael and Jentzen, Walter and Tang, Jun and Chicco, Daniela and Klein, Patrick and Blumenstein, Lars and Basque, Jean-René and Kurth, Jens},
  title = {Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {1},
  pages = {71--78},
  doi = {10.2967/jnumed.123.265448}
}
Kostenlos starten →